Αρχική World News Should Surgery And Radiation Be The Standard Treatment For DCIS? The COMET...

Should Surgery And Radiation Be The Standard Treatment For DCIS? The COMET Study Is Finding Out

About 1 out of every 5 new breast cancer diagnoses are categorized as DCIS (Ductal Carcinoma In Situ), making up roughly 60,000 cases in the United States every year.When women receive a diagnosis of DCIS — also known as Stage 0 cancer or pre-cancer — their doctors often recommend that they get a mastectomy or lumpectomy, in case the cancer becomes aggressive.But what if more doctors adopted a “wait and see” approach?Dr. Shelley Hwang, who is the chief of breast surgery at the Duke Cancer Institute, is leading a study to determine what happens when women don’t immediately go under the knife after a DCIS diagnosis.Photo: Adobe Stock/alfa27
“The estimates are that about 70% of women who are diagnosed with DCIS may never develop invasive cancer,” Dr. Hwang says in the video below, “and so what the study is trying to determine is whether it may be safe to monitor those women rather than intervening early with surgery or radiation.”The results of this study could overhaul how pre-cancer in the breast is treated.A diagnosis of DCIS didn’t even really exist before mammograms. But ever since doctors have been able to see breast cancer at such an early stage — before it has the chance to become invasive — they’ve treated it aggressively.The ten-year survival rate for DCIS is 98% to 99%, so treating it aggressively obviously works. But what if doctors could treat it less aggressively and still get those same results?Photo: Adobe Stock/romaset
“DCIS is treated now as it has been for the past 40 years,” Dr. Hwang said during an interview at the 2017 San Antonio Breast Cancer Symposium (SABCS).Surgery comes with its own side effects, both mental and physical, and a mastectomy often goes hand-in-hand with more surgeries to reconstruct the breast. And if an infection sets in, women undergo even more surgeries.“We’re getting all of these new diagnoses before we really know what’s going to happen,” Dr. Hwang told the Atlanta Journal-Constitution. “The question is what are we going to do with all that information? It creates tremendous anxiety and that leads to a lot of unnecessary procedures.”But, on the flip side, taking a less aggressive approach can make both patients and doctors nervous, and rightly so. Will taking some time to monitor pre-cancer just allow it to become invasive?Photo: Adobe Stock/srisakorn
There is still a lot the medical community doesn’t know about DCIS, like if there are genetic markers or biomarkers that can predict if the pre-cancer will turn invasive, and how long it will take until it does turn invasive.So in 2017, Dr. Hwang began a clinical trial that seeks to find the best treatment path for women with a DCIS diagnosis. It’s called COMET, which stands for Comparison of Operative to Monitoring and Endocrine Therapy.Participants are women who are age 40 or older who have been diagnosed with low-risk DCIS. They are randomly split into two groups: in one group, women undergo the standard treatment for DCIS, which is typically either a lumpectomy or a mastectomy; in the other group, women go under “active surveillance,” which includes regular screenings as well as endocrine therapy (hormone therapy) if needed.Her end goal is to enroll 1,200 women with low-risk DCIS at about 100 cancer centers throughout the US. Currently, 260 women are enrolled and the study is still actively recruiting. (To contact them about enrolling, head to their contact page here.)
Photo: Adobe Stock/freshideaIt will be a few years before results are available.Dr. Hwang knows that active surveillance won’t work for some women, who would perhaps experience heightened anxiety having to wait rather than taking immediate action. There is not a one-size-fits all approach to cancer treatment.Hopefully once we have more information about the nature of DCIS, there will be more options available for treating it effectively without over-treating it, and women can undergo the treatment plan that works best for their situation.Learn more about the trial in this video.Proper BCS greatergood_ctg_abovevideoSource

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...

New Task Force Focuses on Quality of Life for AYAs with Cancer

August 4, 2021, by NCI Staff Adolescents and young adults are using mobile devices to document the impact of cancer and its treatment on their...

Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC

Amivantamab demonstrated robust and durable responses in patients with epidermal growth factor receptor Exon 20 insertion (EGFR Exon20ins)-mutated non-small cell lung cancer (NSCLC) after progression on...